Eledon Pharmaceuticals Inc (ELDN)

Dec 20, 2024

Eledon Pharmaceuticals adjusts CEO bonus structure - Investing.com

Dec 20, 2024

Dec 16, 2024

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Short Interest Update - MarketBeat

Dec 16, 2024

Nov 24, 2024

Eledon Pharmaceuticals (NASDAQ:ELDN) Earns “Buy” Rating from HC Wainwright - Defense World

Nov 24, 2024

Nov 23, 2024

HC Wainwright Has Negative Outlook for ELDN Q4 Earnings - Defense World

Nov 23, 2024

Nov 22, 2024

HC Wainwright Issues Pessimistic Forecast for ELDN Earnings - MarketBeat

Nov 22, 2024

Nov 21, 2024

Eledon Pharmaceuticals retains shares target, Buy rating on clinical trial progress - Investing.com Australia

Nov 21, 2024

Nov 20, 2024

Eledon Pharmaceuticals retains shares target, Buy rating on clinical trial progress By Investing.com - Investing.com South Africa

Nov 20, 2024

Nov 20, 2024

Eledon Pharmaceuticals (NASDAQ:ELDN) Given Buy Rating at HC Wainwright - MarketBeat

Nov 20, 2024

Nov 18, 2024

FY2024 EPS Estimates for ELDN Boosted by Cantor Fitzgerald - MarketBeat

Nov 18, 2024

Nov 15, 2024

Lifesci Capital Issues Optimistic Outlook for ELDN Earnings - MarketBeat

Nov 15, 2024

Nov 15, 2024

ARMISTICE CAPITAL, LLC Acquires Shares in Eledon Pharmaceuticals Inc - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

Eledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) market cap dropped US$48m last week; individual investors who hold 57% were hit as were institutions - Yahoo Finance

Nov 14, 2024

Nov 14, 2024

Institutions along with individual investors who hold considerable shares inEledon Pharmaceuticals, Inc. (NASDAQ:ELDN) come under pressure; lose 16% of holdings value - Simply Wall St

Nov 14, 2024

Nov 14, 2024

Hopkins alum leads Eledon Pharmaceuticals in breakthrough diabetes tegoprubart treatment - Johns Hopkins News-Letter

Nov 14, 2024

Nov 13, 2024

Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results - The Manila Times

Nov 13, 2024

Nov 12, 2024

Eledon Pharmaceuticals Reports Strong Q3 2024 Results - TipRanks

Nov 12, 2024

Nov 12, 2024

Eledon Pharma Surges: $85M Offering, Strong Trial Results Drive Q3 Success | ELDN Stock | ELDN Stock News - StockTitan

Nov 12, 2024

Nov 08, 2024

Amyotrophic Lateral Sclerosis Treatment Market to Grow by USD 663.7 Million from 2024-2028, as Rising Incidence Drives Demand with AI Redefining Market LandscapeTechnavio - The Malaysian Reserve

Nov 08, 2024

Nov 08, 2024

Midday Stock Roundup: Indie Semiconductor Up 43% - Orange County Business Journal

Nov 08, 2024

Nov 06, 2024

Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference - The Manila Times

Nov 06, 2024

Nov 06, 2024

Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation - The Bakersfield Californian

Nov 06, 2024

Nov 06, 2024

Eledon Pharmaceuticals CEO to Present at Guggenheim's First Healthcare Innovation Conference | ELDN Stock News - StockTitan

Nov 06, 2024

Nov 06, 2024

RA Capital Management, L.P. Acquires New Stake in Eledon Pharmac - GuruFocus.com

Nov 06, 2024

Nov 01, 2024

Biotechnology Value Fund L P's Strategic Acquisition in Eledon P - GuruFocus.com

Nov 01, 2024

Oct 31, 2024

ELDN stock touches 52-week high at $4.13 amid robust gains - Investing.com Australia

Oct 31, 2024

Oct 30, 2024

ELDN stock touches 52-week high at $4.13 amid robust gains By Investing.com - Investing.com South Africa

Oct 30, 2024

Oct 30, 2024

SEC Form 424B5 filed by Eledon Pharmaceuticals Inc. - Quantisnow

Oct 30, 2024

Oct 30, 2024

Eledon drug helps transplants 'cure' type 1 diabetes - pharmaphorum

Oct 30, 2024

Oct 29, 2024

Eledon Pharmaceuticals sets terms for $85 million stock offering By Investing.com - Investing.com South Africa

Oct 29, 2024

Oct 29, 2024

Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart (ELDN) - Seeking Alpha

Oct 29, 2024

Oct 29, 2024

Eledon Pharmaceuticals Shares Hit 52-Week High After Positive Trial Data - MarketWatch

Oct 29, 2024

Oct 29, 2024

Promising results for diabetes treatment with new drug By Investing.com - Investing.com Australia

Oct 29, 2024

Oct 29, 2024

Eledon Pharmaceuticals sets terms for $85 million stock offering - Investing.com India

Oct 29, 2024

Oct 29, 2024

Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine - The Manila Times

Oct 29, 2024

Oct 29, 2024

Promising results for diabetes treatment with new drug - Investing.com India

Oct 29, 2024

Oct 29, 2024

Eledon Pharmaceuticals Announces Pricing of $85 Million - GlobeNewswire

Oct 29, 2024

Oct 29, 2024

Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - StockTitan

Oct 29, 2024

Oct 26, 2024

Algorae Pharmaceuticals Plans Major Securities Issuance - MSN

Oct 26, 2024

Oct 24, 2024

Amyotrophic Lateral Sclerosis Treatment Market to hit USD 1.1 billion by 2032, says Global Market Insights Inc. - GlobeNewswire

Oct 24, 2024

Oct 23, 2024

ELDN stock soars to 52-week high, touches $3.35 amid surge - Investing.com

Oct 23, 2024

Oct 04, 2024

Financial Analysis: Eledon Pharmaceuticals (NASDAQ:ELDN) & ABVC BioPharma (NASDAQ:ABVC) - Defense World

Oct 04, 2024

Oct 03, 2024

IgA nephropathy Clinical Trials 2024 (Updated): FDA Approvals, - openPR

Oct 03, 2024

Oct 03, 2024

IgA nephropathy Clinical Trials 2024 (Updated): FDA Approvals, Pipeline, Medication, Therapies, Treatment Market and Companies by DelveInsight - Barchart

Oct 03, 2024

Oct 01, 2024

Eledon Pharmaceuticals completes $4 million equity sale - Investing.com India

Oct 01, 2024

Oct 01, 2024

Eledon Pharmaceuticals completes $4 million equity sale By Investing.com - Investing.com South Africa

Oct 01, 2024